State of the evidence: Laboratory experiments using blood from three healthy donors; not a clinical trial of oral MCP.
What happened in the 2011 study?
The 2011 study directly exposed blood samples and isolated cells from three healthy donors to MCP in the laboratory. It reported activation of selected immune cells and experimental killing activity against K562 cells.[1] Donors were not given MCP and followed for health outcomes. This distinction prevents research using human samples from being mistaken for a human treatment trial.
Human cells are not a clinical trial
Human-derived cells can be valuable for examining a biological question. But adding a material directly to cells in a dish does not reproduce the route an oral product takes through the body. A clinical trial administers an intervention to participants and follows specified outcomes. Demonstrated in human cells and demonstrated to benefit people are therefore different statements that should remain clearly separated.
Why activation is insufficient on its own
An activation marker describes a cellular response under the conditions tested. Whether that response is beneficial, ineffective or unwanted requires further investigation. The immune system should not be treated as a single switch. More activation cannot automatically be interpreted as good news without identifying the desired health outcome. Researchers need to define what success means before a response can support a broader claim.
What a cell-killing assay does not establish
Laboratory activity against a cell line does not show successful treatment of the corresponding disease in people. Contact conditions, duration and environment differ from clinical circumstances. Such an assay may provide a starting point for further research, but claims about cancer treatment or infection prevention require relevant outcomes in the appropriate human population. The name of a test cannot supply that missing evidence.
Keep inflammation claims distinct
Immune-cell activation and reduced inflammation are different outcomes. When both appear in an article, it should explain which measurement supports which statement. A cell experiment cannot establish benefits across all inflammatory diseases. This study also did not identify which patients would benefit from supplementation or which should avoid it. Individual decisions require information beyond the laboratory observation described here.
What readers can conclude
The study investigated interactions between MCP and selected immune cells under laboratory conditions. It does not validate the broad claim of boosted immunity in people. If a description promises fewer infections or improved cancer outcomes, look for human studies that actually measured those endpoints. People with immune-related illnesses or treatments should discuss supplementation with their clinician. This experiment does not establish a personal regimen or dose.
References
This article provides general health information. Research findings about MCP are not individual recommendations for diagnosing or treating disease. Medicine and supplement use should be discussed with a doctor or pharmacist.
Published and sources assessed: 17 October 2026